Neurocrine Will Delay Ongentys Launch, But It Thinks Differentiation Is Clear
Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.
You may also be interested in...
The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.
First quarter financials and COVID-19 impacts from Bausch, Neurocrine, Theravance, Ironwood, Rigel.
Keeping Track Of US FDA Decisions: Approvals For Ongentys And New Keytruda, Darzalex Dosing, But Not For Trevyent
The latest US FDA approval decision news and highlights from the Pink Sheet’s FDA Performance Tracker